Clinical Trials

Sponsor: Cellectar Biosciences

Sponsor Study ID: DCL-16-001

Study Title: An Open Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B Cell Malignancies (CLOVER 1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER WaM)

NCT Number: NCT02952508

Phase: II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Non-Hodgkin's Lymphoma

Study Objectives: Part A of this study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of CLR 131 in patients with WM that have received at least two prior lines of therapy.

For more information about the trial above please contact the study team:

Principal Investigator, Brian Hess, at hessbr@musc.edu.
Study Coordinator, Sarah Britton, at brittosa@musc.edu, or please call +1 843-792-8057.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)